An autologous Treg therapy in development for rheumatoid arthritis (RA), engineered to activate at the site of disease.
SBT7101 is designed to recognize citrullinated protein, a marker present in inflamed tissue, directing the Treg to dampen local inflammation and restore immune balance without lymphodepleting conditioning.
We have initiated a Phase 1 study of SBT7101 in patients with poly-refractory rheumatoid arthritis. For more information, please visit ClinicalTrials.gov.
Engineered Treg therapies for patients with Celiac Disease, inflammatory bowel disease, and other diseases, currently in preclinical development in partnership with Regeneron.
An autologous Treg therapy in development for rheumatoid arthritis (RA), engineered to activate at the site of disease.
SBT7101 is designed to recognize citrullinated protein, a marker present in inflamed tissue, directing the Treg to dampen local inflammation and restore immune balance without lymphodepleting conditioning.
We have initiated a Phase 1 study of SBT7101 in patients with poly-refractory rheumatoid arthritis. For more information, please visit ClinicalTrials.gov.
Engineered Treg therapies for patients with Celiac Disease, inflammatory bowel disease, and other diseases, currently in preclinical development in partnership with Regeneron.
Engineered Treg therapies for patients with Celiac Disease, inflammatory bowel disease, and other diseases, currently in preclinical development in partnership with Regeneron.
Engineered Treg therapies for patients with Celiac Disease, inflammatory bowel disease, and other diseases, currently in preclinical development in partnership with Regeneron.
We collaborate with partners who bring complementary expertise to expand what’s possible for patients with autoimmune disease.
